Macquarie Maintains Outperform on Surgery Partners, Lowers Price Target to $33

Benzinga · 03/11 10:55
Macquarie analyst Tao Qiu maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $34 to $33.